: iStockAnalyst.com Symbols Feed

King Beats, But Earnings Down

Thu, 05 Nov 2009 20:08:54 GMT

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.[More...]

King Pharmaceuticals, Inc (NYSE: KG): Third Quarter Earnings Preview 2009

Thu, 05 Nov 2009 14:35:00 GMT

King Pharmaceuticals, Inc is scheduled to report its fiscal third quarter 2009 financial results on Thursday, November 5, 2009.[More...]

Weekly ETF Spotlight - Pharmaceuticals Gaining

Mon, 24 Aug 2009 18:19:36 GMT

Let's take a look at some of this week's top- and bottom-performing ETFs and ETNs. Keep in mind that we cull the list to avoid duplicate sectors and we toss out Ultra, UltraShorts, 2X, 3X, Inverse, etc. ETFs.[More...]

King Pharmaceuticals (NYSE:KG): Upgraded To Buy At Merrill Lynch/BAM

Fri, 07 Aug 2009 15:27:34 GMT

Merrill Lynch/BAM is upgrading King Pharmaceuticals (NYSE:KG) to Buy from Neutral with a $14 target (prev. $10). Firm notes that while KG faces near-term headwinds, they believe these issues are already largely reflected in the stock’s low relative valuation. They believe that the approval and commercial success of Embeda, which could be the first “abuse-deterrent” opioid available in the US, could drive the shares higher over the next 12 months. Big market opportunity for less abusable product KG’s clinical work has shown that crushed Embeda capsules have a similar abuse potential relative to intact capsules, and significantly lower abuse potential relative to immediate-release morphine. This is important given that opioid abusers commonly crush drug to[More...]

Stock Review: Pain Therapeutics (Nasdaq: PTIE)

Fri, 24 Jul 2009 15:21:35 GMT

Pain Therapeutics is a drug development firm focusing on Remoxy, a tamper-proof version of Oxycontin that could be a big blockbuster for partner King Pharmaceuticals. Read More...[More...]

How To 'Juice' Your Conservative Portfolio

Thu, 09 Jul 2009 19:18:09 GMT

By Jeff Clark You'd be hard-pressed to find a worse time to buy a stock than January 2008. The market was just starting to struggle after the big rally that started in March 2003... the worst credit crisis in generations was in the future... and stocks went on to lose half their value over the next 15 months. Yet by following a strategy I've been writing about for years in these pages, Advanced Income readers who bought on my recommendation in January 2008 are up 40%. I've often written about this strategy as a way of generating income from stocks in a sideways market. And it remains an excellent way of getting juice from a conservative stock portfolio. For most investors, stocks have been relatively juice-free for much of the past two years. The bear market has taken its toll on the "buy and hold" philosophy, and the returns on most[More...]

FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX

Tue, 07 Jul 2009 19:11:39 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 243 entries as of 7/7/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete respon (...)[More...]

FDA Calendar Updates: ACUR, BSX, JAV, KG

Tue, 23 Jun 2009 15:35:47 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

BioMedReports FDA Calendar: 19 Hot Summer Trades

Wed, 17 Jun 2009 12:13:04 GMT

Below is a sample of entries from the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The companies outlined below have expected FDA new drug product decisions or clinical trial results expected over the next three months of summer. The list also includes some Extreme Trades of companies with market caps below $250 million that have pending clinical trial results or FDA decisions that could have a major stock price impact. Rigel Pharma (NASDAQ:RIGL): On 5/5/09, (...)[More...]

FDA Calendar Updates: Royal Returns For King Pharma (NYSE:KG)

Mon, 11 May 2009 16:18:30 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

Durect Q3 Net Loss Narrows

Fri, 30 Oct 2009 13:49:00 GMT

Durect, a US-based specialty pharmaceutical company, has reported a net loss of $5.54 million, or $0.07 per share, for the third quarter ended September 30, 2009, compared to a net loss of $9.16 million, or $0.11 per share, for the third quarter ended September 30, 2008.
Total revenues were $8.38 million for the third quarter of 2009, compared to $6.63 million for the same quarter of 2008.
Net loss for the nine months ended September 30, 2009 was $21.7 million, or $0.26 per share, compared to a net loss of $25.56 million, or $0.33 per share, for the nine months ended September 30, 2008.

: iStockAnalyst.com Symbols Feed

King Beats, But Earnings Down

King Pharmaceuticals, Inc (NYSE: KG): Third Quarter Earnings Preview 2009

Weekly ETF Spotlight - Pharmaceuticals Gaining

King Pharmaceuticals (NYSE:KG): Upgraded To Buy At Merrill Lynch/BAM

Stock Review: Pain Therapeutics (Nasdaq: PTIE)

How To 'Juice' Your Conservative Portfolio

FDA Calendar Updates: KG, PTIE, DRRX, ALTH, TRIB, CBST, DYAX

FDA Calendar Updates: ACUR, BSX, JAV, KG

BioMedReports FDA Calendar: 19 Hot Summer Trades

FDA Calendar Updates: Royal Returns For King Pharma (NYSE:KG)

Durect Q3 Net Loss Narrows

City of Wichita to Fight Westar Rate Merger

New York Hedge Fund Penalized for Not Disclosing Interests in Sale

Westar South Customers May Pay for North's Co2 Emissions

Stocks Tumble on Jobs News

King Pharmaceuticals Reports Q1 Net Loss

King Pharmaceuticals Posts $11M Loss

Three Contracts Show Praxair's Global Reach

Reversal of Fortune 500 Boosts Pittsburgh

Jobless Claims Tally Highest Since 1982

King Pharmaceuticals to Present at Credit Suisse Healthcare Conference

King Pharmaceuticals to Present at UBS Global Life Sciences Conference

Acura Pharmaceuticals and King Pharmaceuticals Provide Update on Acurox® NDA

BenchmarkJournal.Com Free Analyst Review for ANN, GGB, KG, PFG, IAG and QTM

DURECT Signs Long Term Excipient Supply Agreement With King Pharmaceuticals for REMOXY(R)

Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain

King Pharmaceuticals Reports Second Quarter 2009 Financial Results

Pain Therapeutics Reviews Mid-Year Progress, Reports Second Quarter 2009 Financial Results

Ligand Pharmaceuticals Announces Second Quarter Results

Acura Pharmaceuticals Reports Second Quarter 2009 Financial Results

Form 4 BROUILLETTE FREDERICK For: Aug 13 (10K)

Form 4 BROUILLETTE FREDERICK For: Jun 08 (10K)

Form 4 MOYER CHARLES For: Jun 01 (10K)

Form 4 Carter Eric G For: Mar 23 (10K)

Form 4 MARKISON BRIAN A For: Mar 23 (10K)

Form 4 Elrod James W For: Mar 23 (10K)

Form 4 Squicciarino Joseph For: Mar 20 (10K)

Form 4 MARKISON BRIAN A For: Mar 20 (10K)

Form 4 GREEN JAMES E For: Mar 20 (10K)

Form 4 BRUCE ERIC J For: Mar 20 (10K)